John Libbey Eurotext

European Cytokine Network

MENU

Interleukin-6 and cardiac operations Volume 29, numéro 1, March 2018

Illustrations

  • Figure 1
  • Figure 2
  • Figure 3
  • Figure 4
  • Figure 5
  • Figure 6
  • Figure 7
  • Figure 8

Tableaux

Auteur
Department of Cardiothoracic Surgery, The First Hospital of Putian, Teaching Hospital, Fujian Medical University, Putian, Fujian Province, People's Republic of China
* Correspondence
  • Mots-clés : cardiac surgical procedures, inflammation, interleukin-6
  • DOI : 10.1684/ecn.2018.0406
  • Page(s) : 1-15
  • Année de parution : 2018

Interleukin (IL)-6 is a pleiotropic inflammatory cytokine with both pro- and anti-inflammatory capacities, produced by different cells and tissues, such as leukocytes, adipocytes, and endothelium. From the viewpoint of cardiologists, this cytokine is a reliable biomarker of cardiac dysfunction, occurrence of atrial fibrillation, cardiac myxoma with recurrence, remote metastasis or embolization, and atherosclerotic processes. Although IL-6 levels were detected in patients undergoing cardiac operations and reported sporadically, the perioperative kinetics of IL-6 in cardiac surgical patients was insufficiently elaborated. The influencing factors, clinical implications, and causative effects of IL-6 on clinical outcomes and potential treatment choices among cardiac surgical patients remained to be clarified as well. The purpose of this article is to discuss these aspects of IL-6 in patients undergoing a cardiac operation.